Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04

Amphastar Pharmaceuticals, Inc.

2024-Q1 EPS reported $0.81 revenue$171,836,000

Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.
GAAP net income $43.2M ($0.81 dil EPS) vs $26.0M ($0.50) a year ago.
Adjusted non-GAAP net income $55.3M ($1.04 dil EPS) vs $32.1M ($0.62) YoY.
BAQSIMI revenue grew 22% over Eli Lilly's reported Q1 2023 revenue.
No forward guidance provided in the release.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amphastar Pharmaceuticals, Inc. reported the three months ended March 31, 2024 results: revenue $171.8 million, net income $43.2 million, EPS $0.81 per share.

Period: the three months ended March 31, 2024
Revenue: $171.8 million
Net income: $43.2 million
EPS: $0.81 per share
Result: reported results

Exact text from the filing

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2024. First Quarter Highlights ● Net revenues of $171.8 million for the first quarter ● GAAP net income of $43.2 million, or $0.81 per share, for the first quarter

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Amphastar Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001297184-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.